• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阵发性房性心动过速对血栓栓塞事件和主要不良心血管事件的影响:一项单中心回顾性研究。

Impact of Paroxysmal Atrial Tachycardia on Thromboembolic Events and Major Adverse Cardiovascular Events: A Single-Center Retrospective Study.

作者信息

Liu Peng, Lv Tingting, Liu Yuanwei, Zhang Xiaofei, She Fei, He Rong, Li Dan, Liu Lianfeng, Zhang Ping

机构信息

Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, People's Republic of China.

Department of Cardiology, Ordos Central Hospital, Ordos School of Clinical Medicine, Inner Mongolia Medical University, Inner Mongolia, People's Republic of China.

出版信息

Risk Manag Healthc Policy. 2024 Oct 29;17:2587-2598. doi: 10.2147/RMHP.S482876. eCollection 2024.

DOI:10.2147/RMHP.S482876
PMID:39493378
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11531291/
Abstract

OBJECTIVE

Atrial fibrillation (AF) is known to increase the risk of thromboembolic events and major adverse cardiovascular events (MACE). The impact of paroxysmal atrial tachycardia (PAT) on these risks remains unclear.

METHODS

This retrospective cohort study was conducted involving 889 patients diagnosed with PAT and 1106 control patients without PAT, all of whom underwent their initial 24-hour ECG monitoring between 2015 to 2020. Kaplan-Meier survival analysis and Cox regression analysis were used to evaluate the association between PAT and the study endpoints, including thromboembolic events and MACE.

RESULTS

Over a mean follow-up period of 50.3 months, the incidence of thromboembolic events and MACE was significantly higher in the PAT group compared to the control group (6.5% vs 1.7% and 19.1% vs 9.9%, respectively). After adjusting for common risk factors and baseline imbalances, the PAT group exhibited a significantly elevated risk of thromboembolic events (hazard ratio [HR] 3.782, 95% confidence interval [CI] 2.212-6.467; <0.001) and MACE (HR 1.795, 95% CI 1.398-2.305; <0.001). However, the frequency of PAT episodes, heart rate, and maximum heart rate were not significantly associated with these outcomes. Within the PAT group, a history of stroke, transient ischemic attack, and chronic renal failure were identified as independent risk factors for thromboembolic events, while hypertension, coronary heart disease, heart failure, and chronic renal failure were independently associated with MACE.

CONCLUSION

PAT, as detected by 24-hour dynamic ECG, is associated with an increased risk of thromboembolic events and MACE.

摘要

目的

已知心房颤动(AF)会增加血栓栓塞事件和主要不良心血管事件(MACE)的风险。阵发性房性心动过速(PAT)对这些风险的影响尚不清楚。

方法

本回顾性队列研究纳入了889例诊断为PAT的患者和1106例无PAT的对照患者,所有患者均在2015年至2020年间接受了首次24小时心电图监测。采用Kaplan-Meier生存分析和Cox回归分析来评估PAT与研究终点之间的关联,研究终点包括血栓栓塞事件和MACE。

结果

在平均50.3个月的随访期内,PAT组的血栓栓塞事件和MACE发生率显著高于对照组(分别为6.5%对1.7%和19.1%对9.9%)。在调整常见危险因素和基线不平衡因素后,PAT组发生血栓栓塞事件的风险显著升高(风险比[HR]3.782,95%置信区间[CI]2.212 - 6.467;P<0.001)以及MACE的风险(HR 1.795,95%CI 1.398 - 2.305;P<0.001)。然而,PAT发作频率、心率和最大心率与这些结局无显著关联。在PAT组中,卒中病史、短暂性脑缺血发作和慢性肾衰竭被确定为血栓栓塞事件的独立危险因素,而高血压、冠心病、心力衰竭和慢性肾衰竭与MACE独立相关。

结论

通过24小时动态心电图检测到的PAT与血栓栓塞事件和MACE风险增加相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b71f/11531291/6521aee7e474/RMHP-17-2587-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b71f/11531291/37bb14f0dcbb/RMHP-17-2587-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b71f/11531291/2dcd2db25d08/RMHP-17-2587-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b71f/11531291/6521aee7e474/RMHP-17-2587-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b71f/11531291/37bb14f0dcbb/RMHP-17-2587-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b71f/11531291/2dcd2db25d08/RMHP-17-2587-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b71f/11531291/6521aee7e474/RMHP-17-2587-g0003.jpg

相似文献

1
Impact of Paroxysmal Atrial Tachycardia on Thromboembolic Events and Major Adverse Cardiovascular Events: A Single-Center Retrospective Study.阵发性房性心动过速对血栓栓塞事件和主要不良心血管事件的影响:一项单中心回顾性研究。
Risk Manag Healthc Policy. 2024 Oct 29;17:2587-2598. doi: 10.2147/RMHP.S482876. eCollection 2024.
2
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study.心力衰竭对接受利伐沙班治疗的心房颤动患者的临床特征和结局的影响。来自 EMIR 研究的数据。
Cardiol J. 2022;29(6):936-947. doi: 10.5603/CJ.a2022.0091. Epub 2022 Oct 6.
3
Not Baseline Atrial Fibrillation but New-Onset Atrial Fibrillation and the Loss of Left Atrial Function Are Essential for Predicting Poor Outcomes in Non-ischemic Cardiomyopathy.并非基线心房颤动,而是新发心房颤动和左心房功能丧失对于预测非缺血性心肌病的不良预后至关重要。
Front Cardiovasc Med. 2021 Dec 14;8:781125. doi: 10.3389/fcvm.2021.781125. eCollection 2021.
4
Pacemaker-detected atrial fibrillation burden and risk of ischemic stroke or thromboembolic events-A cohort study.起搏器检出的心房颤动负荷与缺血性卒中和血栓栓塞事件风险:一项队列研究。
Heart Lung. 2020 Jan-Feb;49(1):66-72. doi: 10.1016/j.hrtlng.2019.07.007. Epub 2019 Jul 31.
5
Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).心房颤动抗凝治疗患者血栓栓塞和出血事件的风险因素:前瞻性、多中心观察性预防血栓栓塞事件-心房颤动欧洲登记研究(PREFER in AF)。
BMJ Open. 2019 Mar 30;9(3):e022478. doi: 10.1136/bmjopen-2018-022478.
6
A Novel Model for Prediction of Thromboembolic and Cardiovascular Events in Patients Without Atrial Fibrillation.一种用于预测非心房颤动患者血栓栓塞和心血管事件的新模型。
Am J Cardiol. 2020 Sep 15;131:40-48. doi: 10.1016/j.amjcard.2020.06.031. Epub 2020 Jun 28.
7
Association of Regression from Sustained to Paroxysmal Atrial Fibrillation with Clinical Outcomes: The Fushimi AF Registry.从持续性房颤到阵发性房颤的逆转动律与临床结局的关系:伏见房颤注册研究。
Am J Cardiol. 2024 Sep 15;227:37-47. doi: 10.1016/j.amjcard.2024.06.020. Epub 2024 Jun 25.
8
Correlation of paroxysmal supraventricular tachycardia, atrial fibrillation, and sinus rhythm with incidences of new thromboembolic stroke in 1476 old-old patients.1476例高龄患者阵发性室上性心动过速、心房颤动及窦性心律与新发血栓栓塞性卒中发生率的相关性
Aging (Milano). 1996 Feb;8(1):32-4. doi: 10.1007/BF03340112.
9
Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study.非瓣膜性心房颤动合并慢性阻塞性肺疾病患者的主要不良心血管事件:ARAPACIS 研究。
Intern Emerg Med. 2018 Aug;13(5):651-660. doi: 10.1007/s11739-018-1835-9. Epub 2018 Mar 26.
10
Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy.有证据表明,在接受口服抗凝治疗的房颤患者中,D-二聚体水平可预测随后的血栓栓塞和心血管事件。
J Am Coll Cardiol. 2010 May 18;55(20):2225-31. doi: 10.1016/j.jacc.2009.12.049.

本文引用的文献

1
The safety of available pharmacotherapy for stroke prevention in atrial fibrillation.房颤患者卒中预防的现有药物治疗的安全性。
Expert Opin Drug Saf. 2024 Nov;23(11):1371-1380. doi: 10.1080/14740338.2024.2409698. Epub 2024 Oct 1.
2
Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes.在伴有心房快速发作的患者中使用依度沙班进行抗凝治疗。
N Engl J Med. 2023 Sep 28;389(13):1167-1179. doi: 10.1056/NEJMoa2303062. Epub 2023 Aug 25.
3
Device-detected atrial high rate episodes and the risk of stroke/thrombo-embolism and atrial fibrillation incidence: a systematic review and meta-analysis.
器械检测到的心房高心率事件与卒中/血栓栓塞和心房颤动发生率的风险:系统评价和荟萃分析。
Eur J Intern Med. 2021 Oct;92:100-106. doi: 10.1016/j.ejim.2021.05.038. Epub 2021 Jun 19.
4
Is paroxysmal supraventricular tachycardia truly benign? Insightful association between PSVT and stroke from a National Inpatient Database Study.阵发性室上性心动过速真的是良性的吗?一项来自国家住院患者数据库研究的阵发性室上性心动过速与中风之间的深刻关联。
J Interv Card Electrophysiol. 2020 Oct;59(1):35-41. doi: 10.1007/s10840-019-00651-7. Epub 2019 Nov 14.
5
Paroxysmal supraventricular tachycardia and risk of ischemic stroke: A systematic review and meta-analysis.阵发性室上性心动过速与缺血性卒中风险:一项系统评价和荟萃分析。
J Arrhythm. 2019 May 14;35(3):499-505. doi: 10.1002/joa3.12187. eCollection 2019 Jun.
6
Comparison of the New Oral Anticoagulants and Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Systematic Review and Meta-Analysis.新型口服抗凝剂与华法林在伴有心房颤动和心脏瓣膜病患者中的比较:系统评价和荟萃分析。
Drugs R D. 2019 Jun;19(2):117-126. doi: 10.1007/s40268-019-0274-z.
7
Adverse cardiovascular outcomes in atrial fibrillation: Validation of the new 2MACE risk score.心房颤动的不良心血管结局:新的 2MACE 风险评分的验证。
Int J Cardiol. 2017 Dec 15;249:191-197. doi: 10.1016/j.ijcard.2017.09.154. Epub 2017 Sep 18.
8
A prospective study of supraventricular activity and incidence of atrial fibrillation.一项关于室上性活动和房颤发生率的前瞻性研究。
Heart Rhythm. 2015 Sep;12(9):1898-904. doi: 10.1016/j.hrthm.2015.04.042. Epub 2015 May 6.
9
Risk factors and incidence of stroke and MACE in Chinese atrial fibrillation patients presenting to emergency departments: a national wide database analysis.中国急诊科心房颤动患者中风和主要不良心血管事件的危险因素及发生率:一项全国性数据库分析
Int J Cardiol. 2014 May 1;173(2):242-7. doi: 10.1016/j.ijcard.2014.02.040. Epub 2014 Feb 28.
10
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.新型口服抗凝剂与华法林治疗心房颤动患者的疗效和安全性比较:随机试验的荟萃分析。
Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.